BofA lowered the firm’s price target on Zai Lab to $31 from $37 and keeps a Buy rating on the shares. The firm has cut revenue estimates for 2023 and beyond given that in November Zai Lab’s partner announced that the ADVANCE-SC study of efgartigimod on ITP did not meet the primary endpoint. Due to removing the revenue forecast for this indication from its model, the firm reduced revenue forecasts for 2023, 2024 and 2025 by 3%, 7% and 11%, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZLAB: